Volz Yannic, Eismann Lennert, Pfitzinger Paulo L, Jokisch Jan-Friedrich, Buchner Alexander, Schlenker Boris, Stief Christian G, Schulz Gerald B
Department of Urology, Ludwig-Maximilians University, Munich, Germany.
Arab J Urol. 2020 Dec 10;19(1):24-30. doi: 10.1080/2090598X.2020.1859055.
: To conduct a systematic review of whether blood transfusions may be associated with worse outcomes for patients with bladder cancer treated with radical cystectomy (RC), as there has been a recent increase in studies addressing this clinically relevant topic. : PubMed, Ovid Medical Literature Analysis and Retrieval System Online (MEDLINE), Google Scholar, and the ClinicalTrials.gov databases were searched with pre-specified search terms for studies published between January 2010 and May 2020. The systemic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. : A total of 17 studies with 19 627 patients were included after 183 records were screened for eligibility. In all, 10 studies proposed perioperative blood transfusion to be associated with impaired prognosis regarding overall survival, nine studies regarding cancer-specific and four studies regarding recurrence-free survival. The timing of blood transfusion might affect patient outcomes. Notably, several studies did not find a significant correlation between blood transfusions and prognosis. As all studies to date are of retrospective design, the grade of evidence is still limited. : Despite the lack of prospective trials, perioperative blood transfusion may lead to worse oncological outcomes. These results, as well as known non-oncological side-effects and associated costs, are important arguments to carefully consider the indication for blood transfusion. : bladder cancer; CSS: cancer-specific survival; HR: hazard ratio; (N)MIBC: (non-) muscle-invasive BCa; OS: overall survival; PBT, perioperative blood transfusion; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RC: radical cystectomy; RFS: recurrence-free survival.
由于近期针对这一临床相关主题的研究有所增加,因此对接受根治性膀胱切除术(RC)的膀胱癌患者进行输血是否可能导致更差的预后进行系统评价。使用预先指定的检索词,在PubMed、Ovid医学文献分析与检索系统在线版(MEDLINE)、谷歌学术和ClinicalTrials.gov数据库中检索2010年1月至2020年5月发表的研究。系统评价按照系统评价与Meta分析的首选报告项目(PRISMA)指南进行。在筛选了183条记录的合格性后,共纳入了17项研究,涉及19627例患者。总计10项研究提出围手术期输血与总体生存预后受损有关,9项研究涉及癌症特异性生存,4项研究涉及无复发生存。输血时机可能影响患者预后。值得注意的是,几项研究未发现输血与预后之间存在显著相关性。由于迄今为止所有研究均为回顾性设计,证据等级仍然有限。尽管缺乏前瞻性试验,但围手术期输血可能导致更差的肿瘤学结局。这些结果以及已知的非肿瘤学副作用和相关成本,是仔细考虑输血指征的重要依据。膀胱癌;CSS:癌症特异性生存;HR:风险比;(N)MIBC:(非)肌层浸润性膀胱癌;OS:总体生存;PBT:围手术期输血;PRISMA:系统评价与Meta分析的首选报告项目;RC:根治性膀胱切除术;RFS:无复发生存